Angeles Alvarez Secord

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. pmc Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study
    Angeles Alvarez Secord
    Department of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Gynecol Oncol 108:493-9. 2008
  2. ncbi request reprint Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes
    Amanda Nickles Fader
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk A 81, Cleveland, Ohio 44195, USA
    Gynecol Oncol 112:558-62. 2009
  3. doi request reprint Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer
    Angeles Alvarez Secord
    Division of Gynecologic Oncology, Duke Cancer Institute, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Gynecol Cancer 23:846-52. 2013
  4. doi request reprint A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer
    Angeles Alvarez Secord
    Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 128:65-70. 2013
  5. pmc A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer
    Angeles Alvarez Secord
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USA
    Clin Cancer Res 18:5489-98. 2012
  6. doi request reprint A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer
    Angeles Alvarez Secord
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 118:3283-93. 2012
  7. ncbi request reprint Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study
    Angeles Alvarez Secord
    DUMC 3079, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 106:221-32. 2007
  8. ncbi request reprint A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer
    Angeles Alvarez Secord
    Gynecologic Oncology, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 114:442-7. 2009
  9. ncbi request reprint Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer
    Angeles Alvarez Secord
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Box 3079, Duke University Medical Center, Durham, NC 27710, USA
    Int J Clin Oncol 12:31-6. 2007
  10. doi request reprint Attitudes regarding the use of hematopoietic colony-stimulating factors and maintenance of relative dose intensity among gynecologic oncologists
    Angeles Alvarez Secord
    Duke University Medical Center, Durham, NC 27710, USA
    Int J Gynecol Cancer 19:447-54. 2009

Detail Information

Publications58

  1. pmc Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study
    Angeles Alvarez Secord
    Department of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Gynecol Oncol 108:493-9. 2008
    ..This phase II trial assessed the activity and tolerability of cetuximab (C225, Erbitux) in combination with carboplatin in patients with relapsed platinum-sensitive ovarian or primary peritoneal carcinoma...
  2. ncbi request reprint Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes
    Amanda Nickles Fader
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk A 81, Cleveland, Ohio 44195, USA
    Gynecol Oncol 112:558-62. 2009
    ..To determine recurrence patterns and survival outcomes of stage II uterine papillary serous carcinoma (UPSC) patients treated by various modalities with an emphasis on carboplatin/paclitaxel-based chemotherapy (CT)+/-radiotherapy (RT)...
  3. doi request reprint Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer
    Angeles Alvarez Secord
    Division of Gynecologic Oncology, Duke Cancer Institute, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Gynecol Cancer 23:846-52. 2013
    ....
  4. doi request reprint A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer
    Angeles Alvarez Secord
    Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 128:65-70. 2013
    ..To determine if there is an advantage to combination chemotherapy and radiation for optimally resected stage IIIC endometrial cancer (EC)...
  5. pmc A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer
    Angeles Alvarez Secord
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USA
    Clin Cancer Res 18:5489-98. 2012
    ..We conducted a phase I study of dasatinib, an oral SRC-family tyrosine kinase inhibitor, in combination with paclitaxel and carboplatin in the treatment of advanced and recurrent epithelial ovarian cancer...
  6. doi request reprint A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer
    Angeles Alvarez Secord
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 118:3283-93. 2012
    ..The aim of this randomized clinical trial was to evaluate the efficacy and safety of combination (cDC) and sequential (sDC) weekly docetaxel and carboplatin in women with recurrent platinum-sensitive epithelial ovarian cancer (EOC)...
  7. ncbi request reprint Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study
    Angeles Alvarez Secord
    DUMC 3079, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 106:221-32. 2007
    ....
  8. ncbi request reprint A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer
    Angeles Alvarez Secord
    Gynecologic Oncology, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 114:442-7. 2009
    ....
  9. ncbi request reprint Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer
    Angeles Alvarez Secord
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Box 3079, Duke University Medical Center, Durham, NC 27710, USA
    Int J Clin Oncol 12:31-6. 2007
    ..The purpose of this study was to evaluate the toxicity profile of weekly low-dose paclitaxel and carboplatin in patients with gynecologic malignancies...
  10. doi request reprint Attitudes regarding the use of hematopoietic colony-stimulating factors and maintenance of relative dose intensity among gynecologic oncologists
    Angeles Alvarez Secord
    Duke University Medical Center, Durham, NC 27710, USA
    Int J Gynecol Cancer 19:447-54. 2009
    ....
  11. ncbi request reprint Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study
    Angeles Alvarez Secord
    Box 3079, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 101:390-7. 2006
    ..This study examined MASPIN expression in human ovarian cancer, and explored the association between MASPIN and prognosis in patients with advanced stage disease treated with first-line cisplatin, carboplatin and/or paclitaxel...
  12. doi request reprint The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a gynecologic oncology group study
    Angeles Alvarez Secord
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 123:314-9. 2011
    ..To elucidate the regulation of MASPIN expression in epithelial ovarian cancer (EOC) and associations with p53 status and MASPIN promoter methylation...
  13. ncbi request reprint Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer
    A Alvarez Secord
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, West Virginia University Schools of Pharmacy and Medicine, Morgantown, WV 26506, USA
    Int J Hyperthermia 21:333-47. 2005
    ..Liposomal doxorubicin combined with hyperthermia has been shown to increase both liposomal delivery and drug extravasation into tumour xenografts resulting in enhanced cytotoxic effects...
  14. ncbi request reprint The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer
    Angeles Alvarez Secord
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 94:74-9. 2004
    ....
  15. doi request reprint Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer
    Laura J Havrilesky
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 118:386-91. 2012
    ..The objective of the current study was to construct a cost-utility model to compare these 2 regimens with the incorporation of prospectively collected quality-of-life (QoL) data...
  16. ncbi request reprint Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer
    Laura J Havrilesky
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Cente, Durham, North Carolina 27710, USA
    Gynecol Oncol 114:279-83. 2009
    ..To determine factors related to recurrence and survival in women with stage IIIA endometrial cancer; to examine outcomes of women with IIIA1 disease...
  17. doi request reprint Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer
    Paula S Lee
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27708, USA
    Int J Cancer 126:1378-89. 2010
    ..04). MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer...
  18. ncbi request reprint An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC)
    Amanda Nickles Fader
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Cleveland Clinic, Cleveland, OH, USA
    Gynecol Oncol 115:244-8. 2009
    ..However, clinicopathologic risk factors for recurrence are not well understood. This study was undertaken to define the prognostic factors for recurrence and survival in patients with early-stage UPSC...
  19. pmc Expression signatures of TP53 mutations in serous ovarian cancers
    Marcus Q Bernardini
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Toronto, 600 University Avenue, Toronto, Ontario M5G2M9, Canada
    BMC Cancer 10:237. 2010
    ..Mutations in the TP53 gene are extremely common and occur very early in the progression of serous ovarian cancers. Gene expression patterns that relate to mutational status may provide insight into the etiology and biology of the disease...
  20. doi request reprint Adverse events associated with laparoscopy vs laparotomy in the treatment of endometrial cancer
    Jason C Barnett
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, NC, USA
    Am J Obstet Gynecol 205:143.e1-6. 2011
    ..The objective of the study was to compare adverse event rates between laparoscopic vs open surgery for endometrial cancer...
  21. ncbi request reprint The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: prevalence and prognostic significance
    Emily M Ko
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, USA University of North Carolina Lineberger Comprehensive Cancer Center, USA Electronic address
    Gynecol Oncol 133:28-32. 2014
    ..We examined the distribution of obesity, diabetes, and race in Type I and Type II endometrial cancers (EC) and their associations with clinical outcomes...
  22. doi request reprint Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group s
    Elizabeth L Jewell
    Duke University Medical Center 3079, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 115:424-9. 2009
    ....
  23. ncbi request reprint Resection of lymph node metastases influences survival in stage IIIC endometrial cancer
    Laura J Havrilesky
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Box 3079, Durham, NC 27710, USA
    Gynecol Oncol 99:689-95. 2005
    ..Our objective was to compare survival of patients who underwent resection of grossly positive lymph nodes (LN) to those with microscopically positive LN...
  24. pmc Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study
    Laura J Havrilesky
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 26:4144-50. 2008
    ..To determine the cost effectiveness of intraperitoneal versus intravenous regimens for adjuvant treatment of optimally resected stage III ovarian cancer...
  25. ncbi request reprint Outcomes in surgical stage I uterine papillary serous carcinoma
    Laura J Havrilesky
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 105:677-82. 2007
    ..The optimal management of patients with stage I uterine papillary serous carcinoma (UPSC) is unclear. We sought to determine whether outcomes of women with surgical stage I UPSC differ with and without adjuvant therapy...
  26. ncbi request reprint Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study
    Jennifer M Rubatt
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 112:469-74. 2009
    ..The aims of this study were to examine prognostic significance of microvessel density (MVD) in previously-untreated, advanced epithelial ovarian cancer (EOC) and explore associations between MVD and factors that affect angiogenesis...
  27. pmc Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells
    Deanna Teoh
    Division of Gynecologic Oncology, Duke Comprehensive Cancer Center, Durham, NC 27710, USA
    Gynecol Oncol 121:187-92. 2011
    ..To explore the activity of dasatinib alone and in combination with paclitaxel and carboplatin in ovarian cancer cells and to determine if dasatinib activity can be predicted based on evaluation of the SRC pathway...
  28. ncbi request reprint Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer
    Janiel M Cragun
    Duke University Medical Center, Box 3079, Durham, NC 27710, USA
    J Clin Oncol 23:3668-75. 2005
    ..Our goal was to assess effects of the extent of selective lymphadenectomy on outcomes in women with apparent stage I endometrial cancer at laparotomy...
  29. ncbi request reprint A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma
    Leigh A Cantrell
    Division of Gynecologic Oncology, University of Virginia Health System, Charlottesville, VA 22908, USA
    Gynecol Oncol 127:22-6. 2012
    ..To evaluate the impact of adjuvant post-operative therapy in women with early stage uterine carcinosarcoma...
  30. doi request reprint The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer
    Junzo P Chino
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA
    Int J Radiat Oncol Biol Phys 82:1872-9. 2012
    ..We explored the impact of specific RT modalities (whole pelvic RT [WPRT], vaginal brachytherapy [VB]) and LND status on survival...
  31. ncbi request reprint The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma
    Nikki L Neubauer
    Department of Obstetrics and Gynecology, Division of Gynecology Oncology Duke University Medical Center Durham, NC 27710, USA
    Gynecol Oncol 112:511-6. 2009
    ..We sought to assess the accuracy of a preoperative grade 1 designation and role of lymphadenectomy in women with preoperative grade 1 endometrial cancer...
  32. ncbi request reprint Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis
    Laura J Havrilesky
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 107:211-8. 2007
    ..We wished to compare the cost-effectiveness of three chemotherapy regimens for treatment of recurrent platinum-sensitive ovarian cancer...
  33. ncbi request reprint Metformin is associated with improved survival in endometrial cancer
    Emily M Ko
    University of Pennsylvania, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, USA
    Gynecol Oncol 132:438-42. 2014
    ..Preclinical evidence suggests that metformin exhibits anti-tumorigenic effects in endometrial cancer. We sought to investigate the association of metformin on endometrial cancer outcomes...
  34. doi request reprint Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer
    William J Lowery
    Duke University Medical Center, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Durham, NC 27710, USA
    Gynecol Oncol 130:426-30. 2013
    ..To determine if early palliative care intervention in patients with recurrent, platinum-resistant ovarian cancer is potentially cost saving or cost-effective...
  35. doi request reprint Surgical staging for endometrial cancer in the elderly - is there a role for lymphadenectomy?
    William J Lowery
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 126:12-5. 2012
    ..We sought to evaluate the effect of systematic lymphadenectomy (LND) on endometrial cancer-specific survival in an elderly population...
  36. doi request reprint Relationship between tamoxifen use and high risk endometrial cancer histologic types
    Amy E Bland
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 112:150-4. 2009
    ....
  37. doi request reprint Retrospective review of an intraoperative algorithm to predict lymph node metastasis in low-grade endometrial adenocarcinoma
    Patricia A Convery
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 123:65-70. 2011
    ..To validate the Mayo algorithm to intraoperatively identify women with endometrial cancer in whom lymphadenectomy may be safely omitted...
  38. doi request reprint Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence
    Nabila Rasool
    Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Gynecol Oncol 116:10-4. 2010
    ..To study patterns of recurrence and survival outcomes in patients with surgical stage I, grade 3 endometrioid adenocarcinoma of the endometrium (EA) treated with various treatment modalities...
  39. doi request reprint Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer
    Robin A Laskey
    Department of Obstetrics and Gynecology, Duke University Medical Center, USA
    Gynecol Oncol 125:625-30. 2012
    ..To identify factors that increase the risk of neutropenic events in women with advanced ovarian carcinoma receiving initial chemotherapy...
  40. doi request reprint Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer
    Deanna Teoh
    Division of Gynecologic Oncology, Duke Cancer Institute, Durham, NC, USA
    Int J Gynecol Cancer 22:348-59. 2012
    ....
  41. ncbi request reprint Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
    David G Mutch
    Washington University School of Medicine, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, St Louis, MO 63110, USA
    J Clin Oncol 25:2811-8. 2007
    ..On the basis of promising phase II results, gemcitabine was compared with PLD for efficacy and safety in taxane-pretreated Pt-R OC patients...
  42. ncbi request reprint Rectus abdominis myocutaneous and myoperitoneal flaps for neovaginal reconstruction after radical pelvic surgery: comparison of flap-related morbidity
    John T Soper
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Box 3079, Durham, NC 27710, USA
    Gynecol Oncol 97:596-601. 2005
    ..To compare flap-specific complications of rectus abdominis myocutaneous (RAM) and myoperitoneal (RAMP) flap neovagina reconstructions performed concurrently with radical pelvic procedures...
  43. doi request reprint Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression
    Angeles Alvarez Secord
    Division of Gynecologic Oncology, Departments of Medicine, and Medical Oncology, Duke Cancer Institute, Duke University Medical Center, Durham, NC
    Int J Gynecol Cancer 24:218-25. 2014
    ..This study aimed to explore the activity of dasatinib in combination with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells...
  44. doi request reprint Physical strain and urgent need for ergonomic training among gynecologic oncologists who perform minimally invasive surgery
    Jason Franasiak
    Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7570, USA
    Gynecol Oncol 126:437-42. 2012
    ..There is limited data regarding physical strain and minimally invasive gynecologic surgery (MIS). We sought to evaluate ergonomic strain among gynecologic oncologists...
  45. pmc Robotic-assisted laparoscopic gynecologic procedures in a fellowship training program
    Paula S Lee
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    JSLS 13:467-72. 2009
    ..Our goal was to perform an early evaluation of the feasibility of training fellows in robotic-assisted gynecologic procedures at the outset of our incorporation of this technology into clinical practice...
  46. ncbi request reprint Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer
    Rebecca Ann Previs
    Division of Gynecologic Oncology, Duke Cancer Institute, Duke University Medical Center, Durham University of North Carolina School of Medicine, Chapel Hill Department of Pathology, Duke University Medical Center, Durham and Department of Pathology and Laboratory Medicine and Division of Gynecologic Oncology, University of North Carolina, Chapel Hill, NC
    Int J Gynecol Cancer 24:670-5. 2014
    ..The objective of this study was to evaluate prognostic risk factors for survival in women with low-grade serous epithelial ovarian cancer (LGSC)...
  47. doi request reprint Image-guided brachytherapy for gynecologic surgeons
    Junzo Chino
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Surg Oncol Clin N Am 22:495-509. 2013
    ..This article reviews these advances using cervical cancer as a model, and looks to future directions with this promising treatment...
  48. ncbi request reprint The role of PET scanning in the detection of recurrent cervical cancer
    Laura J Havrilesky
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 90:186-90. 2003
    ..Little is known about the efficacy of PET for detecting recurrent disease. We evaluated the potential role of FDG PET in the context of suspected recurrent cervical cancer...
  49. ncbi request reprint High dose rate intraoperative radiotherapy for recurrent cervical cancer and nodal disease
    Ted M Roth
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Box 3079, Durham, NC 27710, USA
    Gynecol Oncol 91:258-60. 2003
    ..Intraoperative radiation therapy (IORT) has demonstrated encouraging results. Patients have traditionally been excluded from IORT if they had distant metastases...
  50. doi request reprint Targeting molecular pathways in endometrial cancer: a focus on the FGFR pathway
    Paula S Lee
    Duke University Medical Center DUMC 3079, Durham, NC 27710, United States Electronic address
    Cancer Treat Rev 40:507-12. 2014
    ..The activity of novel FGFR-targeted agents in preclinical endometrial cancer models and clinical trials will be reviewed. ..
  51. pmc BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas
    Karuna Garg
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Surg Pathol 37:138-46. 2013
    ....
  52. pmc Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome
    Andrew Berchuck
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 15:2448-55. 2009
    ..In the present study, we report on gene expression of early-stage cancers and validate our prognostic model for advanced-stage cancers...
  53. ncbi request reprint Antiangiogenic therapies in epithelial ovarian cancer
    Deanna G K Teoh
    Division of Gynecologic Oncology at Duke Comprehensive Cancer Center, Durham, North Carolina, USA
    Cancer Control 18:31-43. 2011
    ..Therefore, agents that target the angiogenic process are of considerable interest in the treatment of ovarian cancer...
  54. ncbi request reprint Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology
    Christopher V Lutman
    Riverside Gynecologic Oncology, Columbus, OH 43214, USA
    Gynecol Oncol 102:92-7. 2006
    ..To determine whether pelvic lymph node count is associated with patterns of recurrence or survival in patients with FIGO stage I and II endometrial cancer...
  55. ncbi request reprint The role of optimal debulking in advanced stage serous carcinoma of the uterus
    Karen A Moller
    UNC Chapel Hill, CB7570, Chapel Hill, NC 27599, USA
    Gynecol Oncol 94:170-4. 2004
    ..To evaluate the role of optimal surgical cytoreduction and postoperative therapy in women with advanced uterine serous carcinoma (USC)...
  56. ncbi request reprint Cervical cancer
    Benjamin E Greer
    J Natl Compr Canc Netw 6:14-36. 2008